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Apicomplexans are an important group of pathogens that
include the causative agents of malaria, toxoplasmosis, and
cryptosporidiosis. These single-celled eukaryotic parasites evolved
from photosynthetic algae. A remnant chloroplast, called the
apicoplast, is a telltale hold-over from this more benign past in the
ocean. The apicoplast is essential for parasite growth and
development and therefore a potential target for drug therapy.
The fact that humans and animals lack chloroplasts suggests that
using approaches to target the apicoplast may provide parasite
specificity. What are the critical functions of the apicoplast that
should be targeted? In addition to the obvious medical relevance
this question has broader biological implications. Why do
organisms maintain an ancient symbiotic relationship when the
initial rationale for this relationship has fallen by the evolutionary
wayside? A new study by Yeh and DeRisi provides important
clues. Their work demonstrates that antibiotic-induced loss of the
apicoplast in cultured malaria parasites can be chemically rescued
by providing isopentenyl-pyrophosphate (IPP) in the medium. IPP
is generated by the apicoplast resident isoprenoid biosynthesis
pathway and is apparently the one apicoplast metabolite that the
parasite cannot live without in the red blood cell. This finding
could be of great importance for the development of drugs and
vaccines. The ability to produce and maintain parasite lines that
lack the apicoplast also offers exciting experimental possibilities for
the future.
Apicomplexan Parasites, the Dark Side of the
Algal World
Apicomplexans are a phylum of protists that live as intracellular
parasites in a tremendous variety of vertebrate and invertebrate
animals. A number of apicomplexans cause serious disease in
humans. These include, importantly, five species of the genus
Plasmodium, the causative agents of malaria. Malaria remains one
of the most devastating infectious diseases, with a staggering death
toll in particular among small children in sub-Saharan Africa.
Toxoplasma and Cryptosporidium are apicomplexans that cause fetal
and early child hood diseases worldwide, and they are of particular
concern for individuals with a weakened immune system such as
those with HIV-AIDS. Lastly, several apicomplexans, such as
Theileria, Babesia,o rEimeria, threaten the health of domestic
animals and thus indirectly impinge on human health and
prosperity.
Apicomplexans evolved from a photosynthetic ancestor, a
finding that initially took the field of parasitology research by
surprise [1–4]. They are part of a large branch of the eukaryotic
tree of life that is now known as the chromalveolates [5]. This
group came into the world through the merger of two eukaryotic
cells: a protist host and a red algal endosymbiont (Figure 1). Over
time the endosymbiont alga was transformed into the current
chloroplast-like organelle [6]. Many of the chromalveolate kin of
the apicomplexans are algae that harvest sunlight by photosyn-
thesis, including kelps, diatoms, dinoflagellates, and haptophytes.
Collectively they are responsible for the bulk of primary
production and carbon fixation in the ocean. Others, such as
ciliates and oomycetes, have lost their plastids [7]. Apicomplexans
are unique in that they largely maintained the plastid despite the
fact that they are no longer photosynthetic (a few, such as
Cryptosporidium, have lost the organelle [8,9]).
Why Did the Parasites Maintain an Apparently
Pointless Organelle?
A metabolic Catch-22 may mean that these parasites cannot
afford to lose it: A series of pharmacological and genetic studies in
Toxoplasma and Plasmodium has consistently demonstrated that the
apicoplast is essential for parasite growth [10–12]. Chloroplasts in
plants have metabolic functions beyond photosynthesis and
provide the cell with a number of crucial compounds. Genomic
and experimental analyses in apicomplexans suggest that these
nonphotosynthetic functions of the chloroplast are largely
conserved in the apicoplast. The apicoplast is home to biosynthetic
pathways for fatty acids, isoprenoids, iron sulfur cluster assembly,
and a segment of the heme pathway [13,14]. Several of these
compounds are metabolically expensive—they require large
amounts of energy and reduction power to synthesize. Harnessing
the power of photosynthesis directly at its source in the chloroplast
to generate such expensive compounds makes metabolic sense.
The host took advantage of this economy and, through loss of
redundant cytoplasmic pathways, came to rely on the symbiont.
When apicomplexans abandoned photosynthesis instead of
producing metabolites for free, the apicoplast had to be fed with
energy and carbon precursors from the cytoplasm of the parasite
[15,16]. Not only do the pathways have to be fed, but the entire
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import, and replication machinery, has to be maintained
[6,17,18]. Which of the metabolic functions of the apicoplast are
truly essential and thus the reason for its persistence at
considerable cost? This is not an entirely academic question as
the apicoplast is a hotly pursued drug target [19]. This is of
particular importance for malaria, in which drug resistance
develops rapidly [20], requiring a continuous pipeline of novel
antiparasitic compounds. Recent discussion of a renewed effort
towards the goal of malaria elimination will likely require an even
deeper portfolio of drugs [21].
To IPP or Not To Be, That Is the Function
Two biosynthetic pathways known for their importance in the
biology of the plant chloroplast emerged as candidates for the
most critical apicoplast function(s): the synthesis of fatty acids and
isoprenoid precursors. Importantly, both pathways are of
cyanobacterial origin (the bacterial ancestor of all plastids) and
are different from those in their mammalian counterparts
[22,23]. At least in the malaria parasite both pathways appeared
to be the only de novo synthesis machine for these important
metabolites, and antibiotics thought to selectively interfere with
the plastid type pathway inhibited parasite growth [23–25].
Subsequent genetic studies showed that loss of apicoplast fatty
acid synthesis is lethal in Toxoplasma and the liver stages of
Plasmodium, but that it can be tolerated in the clinically most
important red blood cell (RBC) phase of malaria [26–28]. These
findings suggested that in the RBC the parasite can salvage fatty
acids from its host. This left the isoprenoid pathway as the
putative raison d’etre for the apicoplast, and a series of recent
papers now provide robust support for the importance of this
pathway for the parasite [29–31].
Isoprenoids are a large class of biological compounds that
include natural rubbers, cholesterol, ubiquinone, dolichol, farne-
sol, and many others. This tremendous diversity is derived from a
simple five-carbon precursor isopentenyl pyrophosphate (IPP) and
its isomeric form dimethylallyl pyrophosphate (DMAPP). Nature
has devised two mechanistically distinct synthesis routes for IPP
that are named after their key intermediate mevalonate and 1-
deoxy-D-xylulose-5-phosphate (DOXP) pathways. Animals and
fungi use the mevalonate pathway (the target of the blockbuster
drug atorvastatin [Lipitor]), while most bacteria and plants rely on
the DOXP pathway. Apicomplexan parasites depend on their
Figure 1. A metabolic Catch-22 due to evolutionary acquired isoprenoid dependency. Schematic representation of the putative evolution
of the apicoplast and its metabolism. The ancestor of apicomplexans arose from the endosymbiotic merger of a protist host and a single celled red
alga. The host likely benefited from the symbiont’s ability to photosynthesize. Initially there were two redundant isoprenoid synthesis pathways: a
cytoplasmic pathway (likely using the mevalonate pathway as ciliates still do [47]) and a plastid DOXP pathway. Note that both pathways have
multiple enzymatic steps and are shown highly simplified here. The cytoplasmic pathway was lost producing dependency. This forced maintenance
of the apicoplast even after loss of photosynthesis (lower panel). High concentrations of exogenously supplied IPP can overcome this dependency
and thus rescue clindamycin induced loss of the organelle [31] (clindamycin specifically blocks apicoplast protein synthesis). Fos, fosmidomycin;N ,
nucleus; P, plastid; Statin, the active principle of the cholesterol-lowering drug Lipitor).
doi:10.1371/journal.pbio.1001137.g001
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cin, a specific inhibitor of DOXP reductoisomerase, blocks the
growth of malaria parasites in culture and in animal experiments
[23], and mutations in the DOXP pathway are lethal in Toxoplasma
[29]. This demonstrates clearly that the DOXP pathway is
important, but is it the only important function? Yeh and DeRisi
have put this question to an experimental test that is truly elegant
in its simplicity and publish their results in this issue of PLoS Biology
[31]. In experiments in cultured P. falciparum they demonstrate that
parasites can be rescued from the lethal effects of fosmidomycin
treatment when IPP, the final product of the target pathway, is
provided in the medium. This chemical complementation occurs
only with IPP, requires a substantial dose (200 mM), and is not
observed for DMAPP or the alcohol form of IPP, isopentanol.
Next they tested whether IPP rescue also extends to parasites that
are treated with antibiotics that more generally impede the
apicoplast by inhibiting its protein synthesis, such as clindamycin,
doxycycline, or chloramphenicol. Not only does IPP rescue this
treatment, but fascinatingly this apparently cures parasites of their
plastid organelle. When parasites are grown in the continuous
presence of IPP and antibiotic, the organelle and its genome are
lost. These plastid-less strains now depend on a continuous
exogenous supply of IPP, and withdrawal results in swift death.
This seminal finding suggests that the apicoplast and the roughly
500 proteins that work there [32] are ultimately maintained for a
single purpose: the synthesis of a simple isoprenoid precursor. Note
that this is true for the P. falciparum in RBCs and culture medium
and that additional functions are required in other phases of the
life cycle, e.g., in the liver [28].
The Apicoplast and Its Potential for Drugs and
Vaccines
Overall, recent work suggests the DOXP pathway as a prime
target for the development of new antiparasitic drugs. Indeed,
fosmidomycin is effective in the treatment of malaria in people
when combined with a second antibiotic that shows synergism in
targeting the apicoplast [33]. Surprisingly, however, the drug has
no effect on most other apicomplexans [34,35]. While the target
enzyme of fosmidomycin, e.g., in Toxoplasma, appears essential and
drug sensitive, the parasite is nonetheless resistant to concentra-
tions many hundred-fold higher than those needed to inhibit
Plasmodium [29,36]. The key to this conundrum lies in drug access.
While Baumeister and colleagues proposed a model in which the
host cell is the main barrier to drug access [36], we favor the
parasite membrane as the main impediment. In support of this
hypothesis we genetically engineered a parasite capable of drug
uptake, which renders a resistant parasite line fully susceptible in
the absence of any changes in the host cell [29]. Lack of uptake is
similarly responsible for fosmidomycin resistance in Mycobacterium
tuberculosis [37]. At any rate, both studies point to the need for
active drug uptake as an Achilles’ heel of fosmidomycin. A
mutation in the proteins that transport the drug into the parasite
cell or into the apicoplast could rapidly confer drug resistance. The
long-term mainstay of malaria treatment chloroquine fell to
resistance mutations in such a transporter, the food vacuole
protein PfCrt [38]. Eliminating charge from fosmidomycin to
enhance uptake without compromising activity has been challeng-
ing [39], but some moderate enhancement has been achieved
using various ester modifications [40]. The discovery of novel
DOXP pathway inhibitors with more favorable uptake and
pharmacokinetic characteristics is a high priority, and may
produce drugs not only for parasites but also for bacterial disease
such as tuberculosis [41].
Does the finding that IPP is the most critical product of the
apicoplast by Yeh and DeRisi [31] mean that the isoprenoid
pathway is the only apicoplast target worth pursuing? While
targeting the isoprenoid pathway may provide the most direct and
potentially fastest impact, it’s not the only target. Antibiotics that
interfere with apicoplast protein translation are already in clinical
use for malaria and toxoplasmosis [42]. Targeting other aspects of
apicoplast maintenance or metabolism that would ultimately
interfere with the ability of the organelle to supply IPP is a viable
approach that has not been fully explored. We also do not yet
understand what the final isoprenoid product is for which the
parasite so dearly requires IPP. A number of candidates would link
the plastid to mitochondrial function, hormone action, or protein
modification [43,44]. Some of these may be excellent targets.
Exploring these many functions of the apicoplast and its
downstream metabolism is likely a more straightforward task
now that parasites that lack the organelle can be maintained by
chemical complementation [31]. This offers a number of
metabolomic, proteomic, and genetic routes to more fully dissect
apicoplast biology and function. Generating plastid-minus para-
sites potentially could also be a way to produce live attenuated
vaccines. Genetically attenuated parasites have shown some
promise [45]. Recent studies used drugs that target apicoplast
functions to treat early infection and, intriguingly, this treatment
not only effected cure but also generated immunological
protection from reinfection [46]. The new plastid-minus mutant
displays an inherent growth limitation in the absence of IPP that
may act similar to this pharmacological attenuation. Limited
growth is desirable in a vaccine strain. In contrast to dead
parasites, attenuated organisms like the plastid-minus parasites
enter their host cells and initiate development (yet ultimately
succumb to their lack of IPP). This may stimulate the immune
response in a more natural and sustained fashion. Although the
apicoplast provides tremendous opportunities as a target, we have
only begun to understand and exploit its complex biology.
Studying plastidless parasites undoubtedly will be highly informa-
tive.
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